Tara Lynn Barto

Lumacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR

Jennifer L. Taylor‐Cousar, Manu Jain, Tara Lynn Barto et al. · Journal of Cystic Fibrosis · 2017 · 69 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study

Patrick A. Flume, Reta Fischer Biner, D.G. Downey et al. · The Lancet Respiratory Medicine · 2021 · 51 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Sexual and reproductive health experiences and care of adult women with cystic fibrosis

Traci M. Kazmerski, Olivia M. Stransky, Daniel R. Lavage et al. · Journal of Cystic Fibrosis · 2022 · 21 citations

Medicine, Gynecology, Obstetrics +15

Real-life experience with high-frequency chest wall oscillation vest therapy in adults with non-cystic fibrosis bronchiectasis

Tara Lynn Barto, Diego J. Maselli, Sarah Daignault et al. · Therapeutic Advances in Respiratory Disease · 2020 · 18 citations · Full text

Medicine, Clinical Sciences, Healthcare Quality Improvement +9

A phase 3, randomized, double-blind, parallel-group study to evaluate tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating mutation

Edward F. McKone, Emily DiMango, Sivagurunathan Sutharsan et al. · Journal of Cystic Fibrosis · 2020 · 18 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15